Literature DB >> 18068032

HPV and cervical cancer in the 2007 report.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18068032     DOI： 10.1016/S0264-410X(07)01183-8

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  34 in total

1.  Growth inhibition of HeLa cells is a conserved feature of high-risk human papillomavirus E8^E2C proteins and can also be achieved by an artificial repressor protein.

Authors:  Jasmin Fertey; José Hurst; Elke Straub; Astrid Schenker; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

2.  Analysis of risk factors for persistent infection of asymptomatic women with high-risk human papilloma virus.

Authors:  Nianmin Shi; Qiang Lu; Jiao Zhang; Li Li; Junnan Zhang; Fanglei Zhang; Yanhong Dong; Xinyue Zhang; Zheng Zhang; Wenhui Gao
Journal:  Hum Vaccin Immunother       Date:  2017-04-14       Impact factor: 3.452

3.  Epidemiology and risk factors for human papillomavirus infection in a diverse sample of low-income young women.

Authors:  Tasneem Shikary; David I Bernstein; Yan Jin; Gregory D Zimet; Susan L Rosenthal; Jessica A Kahn
Journal:  J Clin Virol       Date:  2009-08-08       Impact factor: 3.168

4.  Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth.

Authors:  Jessica A Kahn; Bret J Rudy; Jiahong Xu; Elizabeth A Secord; Bill G Kapogiannis; Sarah Thornton; Maura L Gillison
Journal:  Sex Transm Dis       Date:  2015-05       Impact factor: 2.830

Review 5.  Development of therapeutic HPV vaccines.

Authors:  Cornelia L Trimble; Ian H Frazer
Journal:  Lancet Oncol       Date:  2009-10       Impact factor: 41.316

6.  Distribution patterns of infection with multiple types of human papillomaviruses and their association with risk factors.

Authors:  Sara Soto-De Leon; Milena Camargo; Ricardo Sanchez; Marina Munoz; Antonio Perez-Prados; Antonio Purroy; Manuel Elkin Patarroyo; Manuel Alfonso Patarroyo
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

7.  Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model.

Authors:  Kosuke Kawai; Gabriela Tannus Branco de Araujo; Marcelo Fonseca; Matthew Pillsbury; Puneet K Singhal
Journal:  BMC Infect Dis       Date:  2012-10-09       Impact factor: 3.090

8.  VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.

Authors:  Ebenezer Tumban; Julianne Peabody; Mitchell Tyler; David S Peabody; Bryce Chackerian
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

9.  Differences in patterns of high-risk human papillomavirus infection between urban and rural low-resource settings: cross-sectional findings from Mali.

Authors:  Nicholas H Schluterman; Samba O Sow; Cheick B Traore; Kamate Bakarou; Rokiatou Dembelé; Founé Sacko; Patti E Gravitt; J Kathleen Tracy
Journal:  BMC Womens Health       Date:  2013-02-06       Impact factor: 2.809

Review 10.  Laboratory and clinical aspects of human papillomavirus testing.

Authors:  Paul K S Chan; María Alejandra Picconi; Tak Hong Cheung; Lucia Giovannelli; Jong Sup Park
Journal:  Crit Rev Clin Lab Sci       Date:  2012 Jul-Aug       Impact factor: 6.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.